Investor Centre

Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
Stat background
1.95 GBX Volume: Market Capitalisation (m) £5.36

Results & AGM 2023

20 - July - 2023
Results and AGM presentation

Grant Success for Glioblastoma studies

20 - June - 2023
Successful notice of a grant for Investigator Sponsored studies of SFX-01 in glioblastoma for collaborator at The Erasmus University Medical Center, Rotterdam, NL.

Investor Meet Company: Results and AGM

21 - July - 2023
CEO Huw Jones and CFO Richard Moulson present an update following the 2023 AGM
Company Analyst
finnCap Mark Brewer

Major Shareholder

Current StakeholderNumber of sharesPercentage holding
J. R. Kight33,100,00012.0%
AXA Framlington23,848,8848.7%
Octopus Investments21,875,0008.0%
SPARK Impact16,186,4465.9%
Seneca Investment Managers14,932,0715.4%
Chelverton Asset Management12,500,0004.5%
RAB Capital8,750,0003.2%
Newlands Capital8,314,8153.0%
The number of ordinary shares in issue is 274,888,117 all of which are in public hands. The Company does not hold any shares in Treasury.
Last updated 20 June 2023